战略性新兴产业框架下的医药企业专利策略与创新能力建设  

Pharmaceutical Corporate Patent Strategy and Innovation Capacity-Building under the Framework of the Strategic Emerging Industries

作　　者：丁锦希[1] 孟立立[1] 张金凤[1] 

机构地区：[1]中国药科大学医药知识产权研究所,南京211198

出　　处：《中国药学杂志》2014年第5期431-436,共6页Chinese Pharmaceutical Journal

基　　金：国家社会科学基金项目(10cFX055);国家知识产权局软课题项目(ss09-A-26;SS11-A-21)

摘　　要：目的为我国医药企业专利策略的开展和创新能力的建设提供可行性建议。方法选取一类创新药物恩必普为实证研究对象,从专利创造、管理和实施3个方面,就该企业如何充分利用国家创新政策和专利战略以提高企业创新能力,保证企业可持续发展进行实证检验。结果恩必普的专利策略获得了较好的实施绩效。结论石药集团形成了专利战略运用与企业创新能力提升相互促进共同发展的良性循环,其成功经验,值得我国高新技术企业学习借鉴。OBJECTIVE To provide domestic innovative pharmaceutical enterprises practical advice on patent strategy and inno- vation capacity-building. METHODS Choose the first class innovative drug NBP as study subject, make an empirical study from three aspects, including patent creation, management and implementation, about how to take full advantage of the national innovation policies and patent strategy to improve the innovation capability of enterprises to ensure its sustainable development. RESULTS The patent strategy of NBP turns out to be a very big success. CONCLUSION CSPC has developed a virtuous cycle, in which patent strategy and innovation capacity-buildingfaeilitate each other,its successful experience is worth learning for high-teeh enterprises.

关 键 词：战略性新兴产业 专利策略 企业创新能力建设 

分 类 号：R95[医药卫生—药学]